⌘K
Loading ticker…
Emergent Biosolutions, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Emergent Biosolutions, Inc. (EBS) has a 3-month relative strength percentile of 51 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 49. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.6%, relative volume 2.15×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
51 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
EBS is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $13M notional. Top 3 carry $37M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $13M |
| XBIState Street SPDR S&P Biotech ETF | 0.18% | $13M |
| IWMiShares Russell 2000 ETF | 0.01% | $11M |
| VXFVanguard Extended Market ETF | 0.01% | $5M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $452K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EBS Jan avg: -2.33% median: 1.72% win: 50% σ: 21.76% n: 4 2022-04-12 → 2026-05-29 | EBS Feb avg: 6.41% median: -17.14% win: 25% σ: 59.20% n: 4 2022-04-12 → 2026-05-29 | EBS Mar avg: -17.79% median: -18.99% win: 25% σ: 15.27% n: 4 2022-04-12 → 2026-05-29 | EBS Apr avg: -10.80% median: -14.77% win: 20% σ: 15.03% n: 5 2022-04-12 → 2026-05-29 | EBS May avg: 46.15% median: 10.81% win: 80% σ: 88.19% n: 5 2022-04-12 → 2026-05-29 | EBS Jun avg: 0.24% median: -2.44% win: 50% σ: 14.28% n: 4 2022-04-12 → 2026-05-29 (current) | EBS Jul avg: 20.93% median: 2.60% win: 50% σ: 44.51% n: 4 2022-04-12 → 2026-05-29 | EBS Aug avg: -13.99% median: -31.25% win: 25% σ: 36.80% n: 4 2022-04-12 → 2026-05-29 | EBS Sep avg: -8.34% median: -6.07% win: 50% σ: 15.02% n: 4 2022-04-12 → 2026-05-29 | EBS Oct avg: 2.71% median: 3.94% win: 50% σ: 32.91% n: 4 2022-04-12 → 2026-05-29 | EBS Nov avg: -9.36% median: -4.05% win: 50% σ: 22.99% n: 4 2022-04-12 → 2026-05-29 | EBS Dec avg: 3.32% median: 3.33% win: 50% σ: 9.37% n: 4 2022-04-12 → 2026-05-29 |